Alnylam Pharmaceuticals Inc. faced a notable decline in its stock price as market reactions to recent developments weighed heavily on investor sentiment.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) experienced a downturn in its stock price, closing down 1.16% today at CA$252.41. This decline comes amid significant company news and broader market conditions that may have influenced investor confidence.
Investor takeaway: Investors should be cautious as Alnylam's recent initiatives, while promising, may not be enough to offset the current market sentiment affecting its stock performance.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$34.25B
P/E
44.7x
52W high
$495.55
52W low
$197.81
1W change
+4.52%
Beta
0.30
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Sep 17, 2026
Wall Street analysts forecast ALNY stock price to rise 45.4% over the next 12 months.
Consensus
Buy4.23 / 5.00
Avg. Target
C$371.35
+45.4% Upside
Current Price
C$255.36
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
46.1%
Annualized
90-Day Vol
77.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$213.60
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$240.60 | C$205.24 – C$282.06 |
| 60 trading days | C$226.70 | C$181.06 – C$283.84 |
| 90 trading days | C$213.60 | C$162.19 – C$281.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
1.16% Decline
Alnylam's stock fell 1.16%, signaling investor concerns amid ongoing developments in the RNA therapeutics market.
Bull case
Alnylam's innovative approach to RNAi therapeutics and the launch of educational initiatives like 'Play by Play' could boost awareness and drive future sales of its products. This might lead to a recovery in stock value.
Bear case
The recent decline in stock price raises concerns about the effectiveness of Alnylam's marketing strategies and the competitive landscape of RNA therapeutics, which could hinder its growth prospects.
Advertisement
Market Reaction to Company News
Alnylam's stock decline coincided with its recent announcement regarding the 'Play by Play' initiative, aimed at raising awareness about ATTR-CM. While the initiative is commendable, investors seem skeptical about its immediate impact on sales and market share in a competitive landscape.
Competitive Landscape and Future Outlook
The RNA therapeutics sector is rapidly evolving, with several competitors emerging. Alnylam's innovative products, including AMVUTTRA, face pressure from other companies in the space. As the market continues to evolve, Alnylam's ability to maintain its competitive edge will be crucial for its long-term success.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
